Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

How Often Do SSRIs and Other New-Generation Antidepressants Lose Their Effect During Continuation Treatment?: Evidence Suggesting the Rate of True Tachyphylaxis During Continuation Treatment Is Low

Zimmerman, Mark, Thongy, Tavi · 2007 · The Journal of Clinical Psychiatry

Abstract

OBJECTIVE: A substantial number of patients who respond to antidepressants experience a relapse despite ongoing pharmacotherapy. The return of symptoms has been interpreted as a loss of the effectiveness of antidepressant activity. However, patients who initially improve while taking antidepressants include an admixture of true drug responders and placebo responders. Consequently, symptom return despite ongoing treatment may not represent a loss of drug effect because the patient may not have experienced a true drug response in the first place. The goal of the present report is to estimate the proportion of relapse attributable to the loss of true drug response versus a loss of placebo response. DATA SOURCES: We reviewed continuation studies of new-generation antidepressants that began as placebo-controlled acute-phase studies. Studies were identified using MEDLINE (English-language articles published from 1980 to 2005 in 23 prespecified journals, using the search terms depression, continuation, and tachyphylaxis). Finally, we identified studies in reference lists of pertinent studies and review articles. STUDY SELECTION: Five studies were reviewed and selected according to the following criteria: continuation studies of new-generation antidepressants that began as placebo-controlled acute-phase studies. One of the studies was excluded from our analyses because it did not report response rates in the acute phase, and we could not find acute-phase response rates in related reports. DATA SYNTHESIS: Using the 2 formulas proposed by Quitkin and colleagues, we estimated the proportion of relapse attributable to the loss of true drug response versus the loss of response attributable to the nonspecific effects of treatment: The relapse rate in placebo responders was 24.1%, whereas the relapse rate in antidepressant responders was 7.4%. Two different methods of estimating relapse suggested that the majority of relapses in patients taking antidepressants during continuation treatment could be attributed to relapses occurring in patients who were not true drug responders. CONCLUSION: Most of the relapse rate during new-generation antidepressant continuation treatment may be due to relapse in patients who were not true drug responders, which suggests that loss of true drug response may be less common than previously thought.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.v68n0814

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 31

Metadata

Authors
Zimmerman, M., & Thongy, T.
Affiliations
Brown University (US)
Venue
The Journal of Clinical Psychiatry
Published
2007-08-15
Volume
68
Issue
08
Pages
1271-1276
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2084249661
Cited by
31
References
0
Citations by year
2023: 1 · 2022: 1 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 3 · 2015: 1 · 2014: 2 · 2013: 2 · 2012: 2
FWCI
1.99
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
selective serotonin reuptake inhibitors, continuation treatment, placebo responders, drug response, tachyphylaxis, depression
MeSH terms
Antidepressive Agents, Depression, Drug Administration Schedule, Humans, Research Design, Tachyphylaxis, Placebo Effect, Selective Serotonin Reuptake Inhibitors, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: How Often Do SSRIs and Other New-Generation Antidepressants Lose Their Effect During Continuation Treatment?: Evidence Suggesting the Rate of True Tachyphylaxis During Continuation Treatment Is Low. https://app.cochat.ai/papers/10.4088/jcp.v68n0814
The paper
Zimmerman, M., & Thongy, T. (2007). How Often Do SSRIs and Other New-Generation Antidepressants Lose Their Effect During Continuation Treatment?: Evidence Suggesting the Rate of True Tachyphylaxis During Continuation Treatment Is Low. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v68n0814

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.